Abnormal expression of activating/inhibitory receptors leads to natural killer (NK) cells dysfunction in tumor. Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumorinfiltrating NK cells from patients with digestive cancers including esophageal, liver, colorectal, gastric and biliary cancer. The increased PD-1 expression on NK cells indicates poorer survival in esophageal and liver cancers. Blocking PD-1/PD-L1 signaling markedly enhances cytokines production and degranulation and suppresses apoptosis of NK cells in vitro. PD-1/PD-L1 exerts inhibitory effect through repressing the activation of PI3K/AKT signaling in NK cells. More importantly, a PD-1 blocking antibody was found to significantly suppress the growth of xenografts in nude mice, and this inhibition of tumor growth was completely abrogated by NK depletion. These findings strongly suggested that PD-1 is an inhibitory regulator of NK cells in digestive cancers. PD-1 blockade might be an efficient strategy in NK cell-based tumor immunotherapy.
INTRODUCTION
Digestive cancers include a heterogeneous group of cancers originating from digestive tract and associated organs. Five of the ten leading causes of cancer death are digestive cancers, which account for over 3 million deaths per year worldwide. 1 Chronic inflammation plays a critical role in most digestive cancers, such as hepatitis-related hepatocellular carcinoma (HCC), Helicobacter pylori infection-related gastric cancer and colitis-related colon cancer. [2] [3] [4] During the process of uncontrolled inflammation, various immune cells are recruited to the microenvironment and contribute to carcinogenesis. 5 Among them, CD8 + T cells and natural killer (NK) cells are critical components. The dysfunction of CD8 + T cells and NK cells has been well described in digestive cancers [6] [7] [8] [9] and is regarded as one of the most important mechanisms leading to disease progression. 10 In fact, immunotherapy aimed at restoring anti-tumor immunity has joined the ranks of surgery, radiation, chemotherapy and targeted therapy as another pillar of cancer therapy. 11 Programmed cell death protein 1 (PD-1) is one of the most important immune checkpoints corresponding to T-cell dysfunction in many solid tumors. 12 PD-1 is expressed on activated T cells. Engagement of PD-1 with programmed death ligand 1 (PD-L1) expressed on cancer cells prevents the expansion and function of effector T cells and eventually results in T-cell exhaustion, thereby leading to tumor immune evasion. 13 Remarkably, monoclonal antibodies against PD-1 and PD-L1 have been approved by the U. S. Food and Drug Administration and have led to impressive and highly encouraging clinical results in the treatment of melanoma and lung cancer. 11 Accumulating data demonstrate increased expression of both PD-1 in T cells and PD-L1 in tumors cells from patients with different types of digestive cancers, including HCC, esophageal squamous cell carcinoma (ESCC), gastric cancer and colorectal cancer. [14] [15] [16] [17] [18] Thus, although related treatments have not yet approved, blocking PD-1/PD-L1 interactions may have potential in the treatment of digestive cancers. 19 NK cells are important cytotoxic innate immune cells that are involved in the elimination of cancer cells. 20 Two main NK cell subsets have been defined on the basis of CD56 and CD16 expression. A CD56 bright CD16 − NK subset produces abundant cytokines including interferon-γ (IFN-γ) and tumor necrosis factor-α, whereas a CD56 dim CD16 + NK subpopulation has high cytolytic activity and releases granules containing perforin and granzymes. 21 The activity of both NK cell subsets is precisely controlled by a series of inhibitory and activating receptors, thus endowing NK cells with the ability to eliminate tumor cells. 21 However, tumor-induced unbalanced expression of activating/ inhibitory receptors hampers NK cell-mediated immune surveillance and promotes tumor progression. As a result, people with advanced cancer often process dysfunctional NK cells, 22 and rescuing the function of NK cells in cancer immunotherapy has been attracting substantial attention. 23, 24 Several studies have detected PD-1 expression on NK cells in various clinical settings; however, the results have not been consistent. [25] [26] [27] [28] [29] [30] [31] [32] PD-1 is highly expressed on peripheral CD56 dim NK cells of healthy donors serologically positive for human cytomegalovirus, 33 whereas PD-1 expression has been reported on CD56
bright NK cells in patients with chronic hepatitis C virus infection. 30 Increased PD-1 expression has been demonstrated in chronic viral infection and acute infection with Citrobacter rodentium but not in acute tuberculosis infection. [17] [18] [19] Several new studies have also reported enhanced PD-1 expression from tumors including multiple myeloma 31 and Kaposi sarcoma. 34 Similarly to observations from studies of viral infection, PD-1 + NK cells from Kaposi sarcoma patients display functional hyporesponsiveness, thus suggesting the involvement of PD-1 in NK functional defects in tumor. 34 However, whether and how PD-1 contributes to perturbing the anti-tumor functions of NK cells remain unclear. Here we provide the first reported evidence that PD-1 expression on NK cells significantly correlates with poor prognosis in digestive cancers. Moreover, in vitro and in vivo studies clearly demonstrated that PD-1/PD-L1 blockade greatly suppresses the growth of HCC xenografts through promoting NK cells functions. (Figures 1c and d) .
RESULTS

Increased
We subsequently examined PD-1 expression on tumorinfiltrating NK (TINK) cells. Both immunofluorescence staining and flow cytometry confirmed PD-1 expression on TINK cells from HCC patients (Figures 2a and b) . Similarly to our results for peripheral NK cells, PD-1 was detected on both CD56 dim CD16 + and CD56 bright CD16 -subsets of TINK cells (Figure 2c ). Furthermore, PD-1 expression on TINK cells was significantly higher than that on infiltrating NK cells from the paired adjacent non-cancerous tissues (Figure 2b ). Interestingly, we observed an extremely high expression of PD-1 on tumor-infiltrated CD49a + NK cells, which have recently been identified as liver resident NK cells in humans 35, 36 ( Figure 2d ). To further evaluate the involvement of PD-1 + NK cells in tumor development, PD-1 expression on peripheral NK cells from ESCC patients and TINK cells from HCC patients were analyzed according to related clinical characteristics. As shown in Figure 1e , PD-1 expression on peripheral NK cells correlated with the degree of tumor differentiation, tumor lymph nodes metastasis stage and metastasis in ESCC. The level of PD-1 expression on peripheral NK cells from patients with G3 stage cancer was higher than that from patients with G2 or G1 stage cancer (left, Figure 1e ). NK cells from ESCC patients with T3~T4 stage cancer exhibited higher PD-1 expression than did patients with T1~T2 stage cancer (middle, Figure 1e ). Accordingly, NK cells from patients with lymph node metastasis had higher PD-1 expression than did patients without lymph node metastasis (right, Figure 1e ). These data supported the notion that PD-1 expression on CD3 − CD56 + NK cells was higher in ESCC patients with poorer prognostic factors. Furthermore, immunofluorescence staining of specimens from 33 HCC patients confirmed the significant correlation of PD-1 expression on CD56 + TINK cells with shorter survival (P = 0.008) (Supplementary Figure S1) . Thus, PD-1 expression on either peripheral or infiltrating NK cells from patients with digestive cancer was significantly upregulated and the increased expression of PD-1 on NK cells predicted a poorer prognosis.
PD-1/PD-L1 blockade increased IFN-γ production and CD107a expression in NK cells PD-1 expression can be induced by either cytokine stimulation or infection. 37 We next examined whether PD-1 on NK cells from digestive cancer could also be regulated. As shown in Figures 3a and b, both phorbol-12-myristate-13-acetate (PMA) and ionomycin or interleukin (IL)-12 and IL-15 stimulation markedly enhanced PD-1 expression on NK cells from ESCC patients in a timedependent manner.
By analyzing the relationship between PD-1 expression and NKcell activation, degranulation and cytokine production, we found that PD-1 + NK cells had higher expression of CD107a and NKG2D but not NKG2A than PD-1 − NK cells (Figure 3c ), a result consistent with findings from a report by Emanuela Marcenaro. 33 To directly assess the involvement of PD-1 in NK cell functions, neutralizing antibodies against PD-L1 were used. Treatment with 2 μg/ml or 8 μg/ml PD-L1 blocking antibodies significantly increased the percentages of both IFN-γ + and CD107a + NK cells from ESCC patients (Figures 3d and e 39 PD-1/PD-L1 interaction blocks PI3K activation, suppresses phosphorylation of AKT and subsequently inhibits T-cell function. 39, 40 PI3K/AKT signaling in NK cells is important for their responsiveness to cytokine stimulation and their cytotoxic functions. 41 Thus we suspected that PD-1 might achieve its effect on NK cells by targeting AKT phosphorylation. Because sorting a sufficient number of NK cells from peripheral blood mononuclear cells requires large amounts of blood, we used NK92 and NKL cells, two human NK-cell lines, to test our hypothesis. After an hour of PMA and ionomycin stimulation, the whole-cell lysates were used to evaluate phosphorylated AKT. As shown in Figure 5a Figure S3) . Anti-PD-1 antibody, which has previously been described as blocking function in vivo, 42 was included for in vivo blocking. Compared with IgG control treatment, anti-PD-1 treatment significantly repressed tumor growth in nude mice (Figures 6a and b) . Ex vivo studies with NK cells isolated from spleen and tumor tissues showed that anti-PD-1 treatment augmented CD69 expression both on spleen and TINK cells (Figures 6c and d) , thus suggesting that PD-1 blockade promoted NK-cell activation, and possibly accounting for the tumor suppression. To further verify the role of NK cells in tumor suppression induced by PD-1 blocking in nude mice, anti-asGM1 was used to deplete NK cells as described in the methods. The NK cell depletion in the spleen and tumor was evaluated by flow cytometry (Figure 6e ). As expected, the inhibition of anti-PD-1 treatment on tumor growth was completely abrogated by NK-cell depletion, thus suggesting that anti-PD-1 treatment exerted its effect through NK cells (Figure 6f ). These data demonstrated that PD-1 blockade enhanced the function of NK cells and suppressed tumor growth in vivo.
DISCUSSION PD-1 is well-known for its critical role in suppressing T-cell activation and proliferation. 43 Blocking antibodies against PD-1/ PD-L1 have been successfully used as new strategies for promoting T-cell-mediated anti-tumor immunity in clinics. 11 Recent data have confirmed PD-1 expression on NK cells in different disease models. 30, 33, 34 However, whether PD-1 blockade + tumor-infiltrating NK cells (right). Cumulative data are shown as mean ± s.e.m., analyzed by Student's t-test. The data were normally distributed and had constant variances. *P ⩽ 0.05, **P ⩽ 0.01, ***P ⩽ 0.001. NK cells are well known as the first line of anti-tumor immunity. Dysfunction of NK cells, including decreased cell number and defects in cytotoxicity, has been reported in many solid tumors. 22, 23 Indeed, various strategies aimed at rescuing NK-cell dysfunction or enhance NK-cell cytotoxicity have been reported and have displayed great potential in tumor therapy. 21 Our data here strongly suggested PD-1 as a potential target to rescue NKcell dysfunction in tumor therapy. First, PD-1 expression was significantly upregulated on peripheral and TINK cells in patients with different digestive cancers. More importantly, the increased PD-1 expression on NK cells correlated well with poor prognosis, such as tumor differentiation grades, tumor metastasis and patients survival (Figure 1 ), thus strongly suggesting the involvement of NK cell-expressed PD-1 in cancer progression. Second, Cumulative data are shown as mean ± s.e.m., analyzed by Student's t-test. The data were normally distributed and had constant variances. *P ⩽ 0.05, **P ⩽ 0.01, ***P ⩽ 0.001. + T-cell exhaustion in many digestive cancers, 19, 44 our data offer evidence of the potential of PD-1 blockade in the treatment of digestive cancers by promoting both CD8 + T cells and NK-cells-mediated immunity. PD-1 expression has been detected on human NK cells from different populations, including healthy donors and patients with tumor or chronic infection. 33 PD-1 might be preferentially expressed on activated NK cells because almost all reported PD-1 + NK cells have come from individuals who had been exposed to antigens, such as tumor antigen, viral antigen and transplantation antigen. 28, 30, 33 Even in the healthy donors, all the subjects with PD-1 + NK cells were seropositive for human cytomegalovirus, thus suggesting exposure to human cytomegalovirus. − and PD-1 + NK cells was compared between the two groups. PMA and ionomycin were applied for 3 h to stimulate activation-induced apoptosis. (c) After preincubation with 8 μg/ml IgG or PD-L1 blocking antibodies (aPD-L1), NK cells isolated from ESCC patients were stimulated with PMA and ionomycin and apoptosis of PD-1 − and PD-1 + NK cells were compared. Cumulative data are shown as mean ± s.e.m., analyzed by Student's t-test. The data were normally distributed and had constant variances. *P ⩽ 0.05, **P ⩽ 0.01, ***P ⩽ 0.001. Accordingly, PD-1 + NK cells displayed higher level of CD69, CD107a, perforin and granzyme than PD-1 − NK cells. 33 Our results showed that activation by either cytokines or PMA quickly and significantly enhanced PD-1 expression on NK cells from ESCC patients (Figure 3) 34 Alternatively, in patients with chronic hepatitis C virus infection, PD-1 expression has been detected on immature CD56 bright NK cells. 30 Here we demonstrated increased PD-1 expression on both CD56 bright and CD56 dim NK cells from patients with digestive cancers (Figures 1c and d) . More interestingly, in HCC specimens, we detected abundant PD-1 expression on infiltrated CD3
+ NK cells, the newly identified hepatic resident NK cells (Figure 2d ). To our knowledge, this is the first report demonstrating the presence of PD-1 on resident NK cells, and our results further suggest the potential role of PD-1 in an NK-cell-mediated dysfunctional tumor microenvironment. Accordingly, PD-1 expression on CD56 + TINK cells suggested shorter survival in HCC patients (Supplementary Figure S1) . Therefore, it is necessary to explore the mechanisms responsible for upregulation of PD-1 on NK cells.
Our data also demonstrated that PD-1/PD-L1 blockade augmented phosphorylation of AKT in NK92 and NKL cells, thus indicating that PD-1 may exert its inhibitory function on NK cells through interfering with PI3K/AKT signaling ( Figure 5 ). In T cells, co-ligation of PD-1 and its ligands results in rapid activation of Src homology region 2 containing tyrosine phosphatase-2 (SHP-2), thus causing dephosphorylation of key signal transducers of activation signaling, for example activation of AKT is consequently stopped. 45 Our data suggested that the biochemical mechanisms by which PD-1 regulates NK and T cells may share much in common. Activation of PI3K/AKT is indispensable in maintaining the appropriate antitumor function of immune cells including NK and T cells. However, activation of the PI3K/AKT signaling in tumor cells is instrumental in promoting tumor development and resistance to anticancer therapies. 46 Numerous efforts have been made to develop PI3K/ AKT/mTOR inhibitors for cancer treatment and several drugs (everolimus and temsirolimus) have been approved by the US. Food and Drug Administration. 46 Our data here together with those from previous studies showing that PD-1 promotes deactivation of AKT in CD8 + T cells 40 strongly suggest the potential side effects of drugs targeting PI3K/AKT signaling, thus limiting the anti-tumor function of PD-1 blockage in immune therapy. Therefore, precautions should be taken when PI3K/AKT targeted therapy is used, and the function of CD8 + T cells and NK cells should be monitored. In conclusion, in this report, we show that the PD-1/PD-L1 signaling mediates NK-cell activation and cytotoxicity. PD-1 expression on NK cells is increased in digestive cancer patients, and is further increased when stimulated. Cancer cells tend to overexpress PD-L1. PD-1/PD-L1 ligation inhibits NK-cell anti-tumor effects, thereby protecting tumor cells from being killed (Figure 7) . Together, these findings provide novel mechanistic data and expand on previous experience with PD-1/PD-L1 blocking antibodies in the treatment of digestive cancers.
MATERIALS AND METHODS
Human subjects and cell lines
A total of 79 subjects, including 42 patients with ESCC, 15 patients with HCC, 6 patients with colorectal cancer, 3 patients with gastric cancer, 1 patient with biliary cancer and 12 healthy individuals, were enrolled in this study. The diagnosis of all patients was confirmed on the basis of surgery and pathology. Blood and tissue samples were collected from the Qilu Hospital of Shandong University between September 2015 and November 2016. The healthy control group was recruited from the Healthy Physical Examination Center of Qilu Hospital. Although the investigators were not blinded during collecting the clinical samples, the involvement of at least two investigators in each step has ensured the validity of the data. The study was approved by the Ethics Committee of Shandong University, and informed consent was acquired from each individual.
EC9706 human ESCC cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Human NK cell line NK92 cells were cultured in NK92 medium (α-medium containing 10% fetal 
Functional assay
Freshly isolated peripheral blood mononuclear cells were used in an NKcell cytokine production assay, degranulation assay and blocking assay. For the cytokine production assay, cells were incubated for 5 h with PMA (50 ng/ml) and ionomycin (1 μg/ml) or IL-12 (12 ng/ml) and IL-15 (100 ng/ ml), and GolgiStop (1:1000). For the degranulation assay, a fluorescenceconjugated anti-CD107a mAb was added as soon as the cells were stimulated, and then the activated cells were collected and stained for surface molecules. For the blocking assay, cells were pretreated with PD-1 blocking antibodies (R&D systems, Minneapolis, MN, USA) or PD-L1 blocking antibodies (Biolegend, San Diego, CA, USA) or matched IgG for 30 min before receiving stimulation. After being processed, the stained cells were analyzed by flow cytometry (BD, FACS Aria II, San Jose, CA, USA).
Flow cytometric analysis
For surface molecules staining, cells were stained with appropriate mixed fluorescence conjugated mAb or isotype controls for 30 min in the dark. For intracellular staining, activated cells were first stained for surface molecules, then fixed with fixation buffer, permeabilized with permealization buffer, and stained for 30 min in the dark with fluorescence-labeled IFN-γ. All of the fluorescence-labeled antibodies were purchased from Biolegend: PE/Cy7-conjugated anti-human CD56 (318318), Percy/cy5.5-conjugated anti-human CD3 (300328), FITC-conjugated anti-human PD-1 (329904), APC-conjugated anti-human CD107a (328620), BV421-conjugated anti-human IFN-γ (502531), Percp/cy5.5-conjugated antihuman CD16 (302028), APC-conjugated anti-mouse CD3(100235), FITCconjugated anti-mouse DX5 (108905) and PE/Cy7-conjugated anti-mouse CD69 (104511).
Apoptosis studies
For the PD-1 cross linking assay, 10 6 peripheral blood mononuclear cells were cultured in 24-well plates (Corning, Corning, NY, USA) in the absence or presence of plate-bound anti-human PD-1(R&D systems) (10 μg/ml). For the PD-L1 blocking assay, cells were pre-incubated with human anti-PD-L1 blocking mAb, at 2 μg/ml for 30 min at 37°C before being cultured in 24-well plates. PMA and ionomycin stimulation was used for activationinduced apoptosis. Three hours later, the cells were collected and surface stained with APC-labeled CD3-PE, CD56-PE/cy7, and PD-1-PE/dazzle and subsequently with annexin V-FITC. Stained cells were then analyzed using flow cytometry.
Cell lysis and western blotting
Cells were lysed in RIPA lysis buffer containing 1% phenylmethanesulfonyl fluoride and 1% phosphatase inhibitor cocktail. Proteins were resolved by SDS-PAGE and transferred to polyvinylidene fluoride membranes. Rabbit anti-phospho-Akt antibody (CST 4691p), rabbit anti-Akt antibody (CST 4060p), mouse anti-GAPDH antibody (Goodbio,GB11002) and secondary horseradish peroxidase-conjugated antibodies were used for the assay. The proteins were detected using an ECL detection system (Thermo Fisher Scientific, San Jose, CA, USA).
Tissue microarrays and immunofluorescence microscopy
Tissue microarrays containing 33 HCC tissue cores (2 mm in diameter, Supplementary Table S1) were ordered from the Shanghai Outdo biotech company (HLiv-HCC180Sur-05). For immunofluorescence double staining, sections were first deparaffinized and then incubated with retrieval solution (ZSGB-Bio, Beijing, China) for 15 min in a microwave oven. After treatment with 10% goat serum at 37°C for half an hour, the tissues were incubated with anti-CD56 (Abcam, Cambridge, MA, USA) and anti-PD-1(Abcam) antibodies overnight. The sections were then incubated with FITC or PElabeled secondary antibodies (ZSJQ-Bio). 4',6-diamidino-2-phenylindole was used for counterstaining. The staining was detected on a Zeiss DM2500 microscope with × 20 objectives.
PD-1 blockade and NK-cell depletion in nude mice with xenografts of EC9706 cells
For the xenograft assay, 3 × 10 6 EC9706 cells were injected subcutaneously into the right flanks of 5-week-old male nude mice. The minimum sample size, five mice per group, is calculated using Sigma Stat3.5 on the basis of preliminary experimental data (probability level of 0.05 and power of 0.80). Ten mice were numbered from 1 to 10 and randomly divided into two groups with the help of random number table. Anti-PD-1 antibodies (BioXcell, West Lebanon, NH, USA) or IgG (BioXcell) were administered i.p. to mice 1 day after injection, and once every 3-4 days for 2 weeks. Tumor size was measured every 3-4 days with a caliper. The tumor volume was calculated according to the formula: volume = (length × width 2 )/2. NK-cell depletion was achieved by i.p. injection of 30 μl undiluted anti-asialo GM1 antibodies (Wako Pure Chemical Industries, Osaka, Japan) every 4-5 days, starting 2 days before EC9706 cells engraftment, thus resulting in 480% depletion of CD3 − CD49b (DX5) + NK cells in the nude mice as determined by flow cytometry. Animals were killed 17 days later. NK cells infiltrating in the spleen and tumor were extracted as previously described. 48 Although no blinding was carried out during the process, the involvement of at least two investigators in each step has ensured the validity of the data. All of the animal studies were approved 
Statistical analysis
The clinical sample size was calculated using Sigma Stat3.5 to ensure the validity of the results. Data are reported as mean values ± s.e.m. All data were analyzed using GraphPad Prism 5.0. All data were normally distributed and had constant variances. The statistical significance of differences between two groups was determined by Student's t-test. P-values o0.05 were considered significant.
